Vascular parkinsonism is a form of parkinsonism caused not by the progressive loss of dopamine-producing brain cells seen in Parkinson’s disease, but by damage to the brain’s blood vessels. It accounts for a meaningful share of all parkinsonism cases and most often shows up as difficulty walking and balance problems concentrated in the lower body, with relatively little of the hand tremor people associate with Parkinson’s disease. The condition is driven by cerebrovascular disease, particularly damage to small blood vessels deep in the brain, and the distinction from Parkinson’s matters because it changes what treatments work and what risks lie ahead.
What Causes Vascular Parkinsonism
The underlying engine of vascular parkinsonism is cerebral small vessel disease. Over time, chronic high blood pressure, diabetes, and other vascular risk factors damage the tiny arteries that supply the brain’s deep white matter and basal ganglia. This damage leads to two hallmark findings on brain scans: white matter lesions and small lacunar infarcts, which are essentially tiny strokes deep in the brain tissue. These lesions disrupt the neural circuits that coordinate movement, particularly the loops connecting the cortex, basal ganglia, and back to the cortex.
What makes this fundamentally different from Parkinson’s disease is which structures are damaged and why. In Parkinson’s, dopamine-producing neurons in a midbrain region called the substantia nigra slowly die off. In vascular parkinsonism, the substantia nigra is usually intact. Instead, the ischemic damage interrupts the wiring that connects movement-control centers to one another. Because the problem is disrupted connections rather than missing dopamine, the condition behaves differently and responds differently to medication.
Autopsy studies of people with vascular parkinsonism reveal multiple subcortical ischemic lesions concentrated in the basal ganglia and deep white matter, with less frequent involvement of the striatum or substantia nigra directly. The damage to these circuits explains the prominent gait and balance problems that define the condition clinically.
Three Recognized Subtypes
An international working group has proposed dividing vascular parkinsonism into three subtypes, and understanding which one applies matters for prognosis and treatment decisions.
- Acute or subacute post-stroke type: This develops after a stroke that directly damages the nigrostriatal pathway. Symptoms tend to be one-sided, resembling classic Parkinson’s disease, and these patients are the most likely to respond to dopaminergic medication.
- Insidious-onset type: This is the most common form. It develops gradually as small vessel disease accumulates white matter lesions and lacunar infarcts over years. Symptoms are symmetrical, concentrated in the legs and trunk, and patients typically respond poorly to levodopa.
- Mixed type: Some patients have both vascular damage and a neurodegenerative process like Parkinson’s disease occurring simultaneously. These individuals may show features of both conditions, including upper and lower body rigidity, resting tremor, and dementia, and they tend to have a partial response to levodopa.
The insidious-onset subtype dominates clinical practice and is what most clinicians mean when they refer to vascular parkinsonism without further qualification. Neuroimaging in this group shows brain atrophy alongside widespread deep white matter lesions and lacunar infarcts, with only rare direct damage to the nigrostriatal areas that are the primary target in Parkinson’s disease.
How the Symptoms Differ from Parkinson’s Disease
The symptom profile of vascular parkinsonism has a characteristic pattern that experienced clinicians learn to recognize, though the overlap with Parkinson’s disease can still make diagnosis tricky. The hallmark presentation is symmetrical lower-body parkinsonism: stiffness and slowness that affect the legs and trunk more than the arms and hands. Patients develop a shuffling, magnetic gait where their feet seem stuck to the floor, along with marked postural instability that leads to frequent falls. Resting tremor, the symptom most people picture when they think of Parkinson’s, is typically absent or minimal.
Beyond the motor symptoms, vascular parkinsonism brings a broader constellation of problems. Patients frequently develop pseudobulbar signs affecting speech and swallowing, pyramidal signs like brisk reflexes, and urinary incontinence. These additional features reflect the widespread nature of the underlying small vessel disease, which damages multiple brain circuits beyond just those controlling movement.
People with vascular parkinsonism also tend to be older at symptom onset than those with typical Parkinson’s disease, and the condition progresses somewhat differently. Rather than the gradual, one-sided onset that characterizes early Parkinson’s, vascular parkinsonism often presents with bilateral symptoms from the start and may progress in a stepwise fashion, worsening after new small strokes.
Cognitive and Psychiatric Effects
Cognitive impairment is common in vascular parkinsonism and tends to be broader and more severe than what is seen early in Parkinson’s disease. Research has found that patients show a global pattern of cognitive decline affecting executive function, verbal memory, and language. This makes sense given the widespread nature of the small vessel damage: the same white matter lesions that disrupt motor circuits also damage pathways involved in thinking, planning, and remembering.
Dementia can develop as the vascular damage accumulates, and the cognitive profile overlaps with what is seen in vascular dementia more broadly. In fact, vascular parkinsonism and vascular dementia share the same underlying pathology of cerebral small vessel disease; they are in many ways different clinical expressions of the same process, differing mainly in which brain circuits bear the heaviest burden of damage.
Apathy is another frequent feature, though its relationship to vascular damage is complicated. While small vessel disease can directly damage motivational circuits in the brain, depression and cognitive deterioration also contribute to apathy in these patients, making it hard to attribute the symptom to any single cause. This matters clinically because treating depression may partially improve the apathy, even if the vascular damage itself is irreversible.
Some degree of autonomic dysfunction also occurs. One study found that patients with vascular parkinsonism showed a significantly decreased coefficient of variation in heart rate variability compared to controls, suggesting subtle autonomic nervous system involvement, though the clinical consequences are less dramatic than the motor and cognitive symptoms.
How Vascular Parkinsonism Is Diagnosed
There is no single test that definitively confirms vascular parkinsonism. Diagnosis rests on a combination of clinical findings and brain imaging, assessed against proposed diagnostic criteria. The most widely referenced criteria require three elements: the presence of parkinsonism, evidence of cerebrovascular disease on MRI or CT, and a plausible relationship between the two. That relationship can take the form of sudden parkinsonism after a stroke affecting the nigrostriatal pathway, or gradual development of parkinsonism alongside accumulating small vessel disease in the white matter.
Standard MRI is the workhorse of diagnosis. Patients with vascular parkinsonism show significantly more severe white matter changes and brain atrophy than those with Parkinson’s disease when scored on established rating scales. Advanced MRI techniques including volumetry, diffusion tensor imaging, and sequences that visualize the substantia nigra are being developed to improve diagnostic accuracy further, though these remain largely research tools for now.
Dopamine transporter imaging (commonly known as a DaTSCAN) can be useful for distinguishing the two conditions. In Parkinson’s disease, this scan typically shows markedly reduced dopamine transporter uptake in the striatum, usually worse on one side. In the common insidious-onset form of vascular parkinsonism, uptake tends to be more symmetrically preserved or only mildly reduced, because the dopamine-producing neurons themselves are not the primary target of the disease. A meta-analysis found that dopamine transporter imaging achieved sensitivity above 85% and specificity above 80% for distinguishing Parkinson’s disease from vascular or drug-induced parkinsonism.
There is an important caveat, though. Patients with vascular parkinsonism who have asymmetric basal ganglia lesions can show asymmetric DaTSCAN findings that closely mimic Parkinson’s disease, creating a diagnostic pitfall. The scan is a helpful tool, not a perfect one.
Conditions That Look Similar
Vascular parkinsonism does not exist in a diagnostic vacuum. Several other conditions produce overlapping symptoms and imaging findings, and distinguishing between them is one of the genuine challenges in neurology.
Idiopathic normal pressure hydrocephalus is perhaps the trickiest mimic. It presents with the same triad of gait disturbance, cognitive impairment, and urinary incontinence that is common in vascular parkinsonism, and brain imaging in both conditions can show enlarged ventricles. The distinction matters because normal pressure hydrocephalus is potentially treatable with a shunt to drain excess cerebrospinal fluid. Researchers have explored using cerebrospinal fluid pressure measurements and specific MRI morphometry to separate the two conditions, but the overlap remains a real clinical problem.
Progressive supranuclear palsy, another neurodegenerative condition that causes falls and gait problems, can also resemble vascular parkinsonism. A computed measure called the Magnetic Resonance Parkinsonism Index, which compares the size of specific brainstem structures on MRI, has shown promise in distinguishing the two with high accuracy when a specific cutoff is applied. But this tool is not yet part of routine clinical practice everywhere.
When Vascular Disease and Parkinson’s Disease Coexist
The mixed subtype of vascular parkinsonism deserves special attention because it is probably more common than many clinicians realize. A large community-based autopsy study of over 1,750 older adults found that Lewy body pathology (the hallmark of Parkinson’s disease) was present in about a quarter of participants, while cerebrovascular disease pathologies were present in more than two-thirds. Both Lewy bodies and three types of vascular pathology, including atherosclerosis, arteriolosclerosis, and large infarcts, were each independently associated with the severity of parkinsonian signs near the time of death.
This means that in many older adults, parkinsonism is not purely one thing or the other. The vascular damage and neurodegenerative damage compound each other, each contributing independently to how stiff, slow, and unsteady someone becomes. For clinicians, this has practical implications: a patient whose brain scan shows significant small vessel disease may still have underlying Parkinson’s pathology that could benefit from dopaminergic medication. Conversely, a patient diagnosed with Parkinson’s disease who seems to be declining faster than expected may have unrecognized vascular disease accelerating the process.
Treatment and Why Levodopa Often Falls Short
Levodopa, the gold-standard medication for Parkinson’s disease, is the first drug tried in most cases of vascular parkinsonism, but expectations need to be calibrated. A systematic review and meta-analysis found that the response rate to levodopa in vascular parkinsonism was roughly 30%. That is substantially lower than the dramatic improvement most Parkinson’s disease patients experience, but it is not zero, and the response was not random. The odds of responding well were about 15 times higher in patients whose vascular damage specifically involved the nigrostriatal pathway compared to those whose damage lay elsewhere.
The reason levodopa often fails in vascular parkinsonism traces directly back to the underlying pathology. Levodopa works by replenishing dopamine in the brain, which helps when the problem is a shortage of dopamine-producing cells. But in the common insidious-onset form of vascular parkinsonism, the dopamine system is relatively intact. The problem instead is that ischemic damage has destroyed the white matter connections that carry signals between brain regions. Replacing dopamine does nothing for broken wiring.
This is why a trial of levodopa serves a dual purpose: it may help the subset of patients with nigrostriatal involvement, and the degree of response provides diagnostic information. A patient who responds dramatically is more likely to have either the acute post-stroke subtype or a mixed picture with coexisting Parkinson’s disease. A patient who shows no benefit likely has the more common form with predominantly white matter and subcortical damage.
Beyond levodopa, treatment focuses heavily on managing vascular risk factors. Controlling blood pressure, treating diabetes, managing cholesterol, and stopping smoking are all critical for slowing the accumulation of further small vessel damage. This is not a cure, but it addresses the root cause of disease progression in a way that symptomatic medication cannot.
Physical Rehabilitation
Because the motor problems in vascular parkinsonism are dominated by gait difficulty and balance impairment rather than tremor, physical therapy plays a particularly important role. Walking problems are the chief source of disability and fall risk in these patients, and they tend to respond poorly to medication.
Gait training approaches have shown promise. One case study using body weight-supported treadmill training in a patient with vascular parkinsonism found significant improvements in timed walking tests during the phases when treadmill training was added to standard physical therapy, with performance declining when the treadmill training was withdrawn and improving again when it was reintroduced. While a single case study cannot establish a treatment as proven, the results fit with broader rehabilitation principles: task-specific, repetitive gait training helps the brain find alternative movement strategies even when the original pathways are damaged.
Balance training, resistance exercises for the legs, and programs targeting fall prevention are standard components of rehabilitation for these patients. The evidence base is thinner than for Parkinson’s disease rehabilitation specifically, partly because vascular parkinsonism has been studied less and partly because clinical trials struggle with the heterogeneity of the condition. In practice, most rehabilitation specialists apply approaches that have worked in both Parkinson’s disease and stroke recovery, adapting to the individual patient’s deficits.
Prognosis and Ongoing Vascular Risk
Vascular parkinsonism carries risks beyond the movement disorder itself. A study comparing patients with small vessel disease to controls found that about a quarter of those with vascular parkinsonism experienced further vascular events or died during follow-up, compared to just 6% of controls. After adjusting for age, sex, and other vascular risk factors, having vascular parkinsonism was associated with roughly a sevenfold higher risk of vascular events or death.
This elevated risk makes aggressive management of cardiovascular health essential, not optional. Stroke, heart attack, and further accumulation of brain damage are all ongoing threats. Patients and their families should understand that vascular parkinsonism is fundamentally a disease of the blood vessels, and everything that protects blood vessels, from medication management to lifestyle changes, is part of treating the condition, not just secondary prevention.
The trajectory of vascular parkinsonism also tends to differ from Parkinson’s disease. Rather than a smooth, predictable decline, the course can be punctuated by sudden worsenings when new vascular events occur, followed by partial recovery. Some patients remain relatively stable for long periods if no new strokes develop, while others decline more steadily as small vessel disease slowly accumulates. The variability makes individual prognostication genuinely difficult, even for experienced clinicians.
Autonomic Involvement and Overlooked Features
While vascular parkinsonism is rightly defined by its motor features, the non-motor dimensions deserve attention. Urinary incontinence, which tends to appear earlier and be more prominent than in Parkinson’s disease, can profoundly affect quality of life and is often undertreated because the focus stays on walking and balance. Pseudobulbar affect, where patients laugh or cry in ways that do not match their emotional state, can be distressing and socially isolating. Speech and swallowing difficulties progress in some patients and carry risks of aspiration pneumonia.
Heart rate variability findings suggest that autonomic control is affected in vascular parkinsonism, though the mechanism differs from the autonomic dysfunction seen in Parkinson’s disease, where the peripheral autonomic nerves themselves degenerate. In vascular parkinsonism, the autonomic changes likely reflect central damage to brainstem and white matter circuits that regulate autonomic function. The practical difference is subtle for patients, but it does mean that some of the severe autonomic complications seen in advanced Parkinson’s, such as dramatic blood pressure drops upon standing, may be less prominent in pure vascular parkinsonism.
Addressing these non-motor symptoms often requires a coordinated team approach. Urological management, speech therapy, psychological support for mood and apathy, and careful medication review to avoid drugs that worsen parkinsonism all contribute to maintaining quality of life as the condition evolves.